Table 6. Significance of the presence of... | American Society of Hematology

Table 6.

Significance of the presence of secondary abnormalities among patients with inv(16) or t(16;16), t(8;21), or t(9;11)

Cytogenetic abnormality	No. of patients	% CR	P	5-y CIR (SE)	P	% 5-y OS (95% CI)	P
inv(16) or t(16;16)
Sole	64	86		0.67 (0.06)		53 (41-65)
With at least 1 secondary abnormality	32	84	1.0^9-150	0.30 (0.09)	.002^9-150	65 (47-80)	.30^9-150
Sole or with 1 secondary abnormality	88	85		0.56 (0.06)		59 (48-69)
Complex with at least 3 abnormalities	8	88	1.0^9-151	0.43 (0.21)	.42^9-151	38 (16-66)	.45^9-151
t(8;21)
Sole	22	95		0.43 (0.11)		54 (34-73)
With del(9q)	18	94	1.0^9-150	0.53 (0.13)	.52^9-150	61 (39-80)	.83^9-150
With −X or −Y	38	92	1.0^9-150	0.46 (0.09)	.88^9-150	50 (33-66)	.77^9-150
With + 8	8	88	1.0^9-150	0.29 (0.19)	.81^9-150	50 (24-76)	.40^9-150
With any other secondary abnormality	6	67	.11^9-150	ND	ND	67 (33-89)	.92^9-150
Sole or with 1 secondary abnormality	67	93		0.52 (0.06)		49 (36-61)
Complex with at least 3 abnormalities	14	86	.60^9-151	0.25 (0.13)	.07^9-151	64 (40-83)	.28^9-151
t(9;11)
Sole	12	75		0.67 (0.18)		33 (15-58)
With at least 1 secondary abnormality	15	93	.29^9-150	0.50 (0.14)	.33^9-150	47 (23-71)	.52^9-150
Sole or with 1 secondary abnormality	19	84		0.50 (0.13)		42 (23-64)
Complex with at least 3 abnormalities	8	88	1.0^9-151	0.71 (0.20)	.55^9-151	38 (14-69)	.56^9-151

Cytogenetic abnormality	No. of patients	% CR	P	5-y CIR (SE)	P	% 5-y OS (95% CI)	P
inv(16) or t(16;16)
Sole	64	86		0.67 (0.06)		53 (41-65)
With at least 1 secondary abnormality	32	84	1.0^9-150	0.30 (0.09)	.002^9-150	65 (47-80)	.30^9-150
Sole or with 1 secondary abnormality	88	85		0.56 (0.06)		59 (48-69)
Complex with at least 3 abnormalities	8	88	1.0^9-151	0.43 (0.21)	.42^9-151	38 (16-66)	.45^9-151
t(8;21)
Sole	22	95		0.43 (0.11)		54 (34-73)
With del(9q)	18	94	1.0^9-150	0.53 (0.13)	.52^9-150	61 (39-80)	.83^9-150
With −X or −Y	38	92	1.0^9-150	0.46 (0.09)	.88^9-150	50 (33-66)	.77^9-150
With + 8	8	88	1.0^9-150	0.29 (0.19)	.81^9-150	50 (24-76)	.40^9-150
With any other secondary abnormality	6	67	.11^9-150	ND	ND	67 (33-89)	.92^9-150
Sole or with 1 secondary abnormality	67	93		0.52 (0.06)		49 (36-61)
Complex with at least 3 abnormalities	14	86	.60^9-151	0.25 (0.13)	.07^9-151	64 (40-83)	.28^9-151
t(9;11)
Sole	12	75		0.67 (0.18)		33 (15-58)
With at least 1 secondary abnormality	15	93	.29^9-150	0.50 (0.14)	.33^9-150	47 (23-71)	.52^9-150
Sole or with 1 secondary abnormality	19	84		0.50 (0.13)		42 (23-64)
Complex with at least 3 abnormalities	8	88	1.0^9-151	0.71 (0.20)	.55^9-151	38 (14-69)	.56^9-151

Abbreviations are explained in a footnote to Table 5.

For comparison with the sole group.

For comparison with the group comprising patients with sole primary abnormality and those with 1 secondary abnormality.